IP Library Granted Patent US 12,220,559
Granted Patent B2
US 12,220,559 · App. 18/132,510 · Granted Feb 11, 2025

System for administering a medicament

Inventors: Michael Robert Mensinger (San Diego, CA); Sean Saint (San Diego, CA)
Assignee: Medtronic MiniMed, Inc.
A61M5/20A61M5/31568A61M5/31571G16H10/60G16H20/10G16H40/63A61M5/31525A61M2205/3553A61M2205/50A61M2205/52A61M2205/581A61M2205/582A61M2205/583A61M2205/8206G16H20/17G16H40/67
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,220,559
App. No.
18/132,510
Granted
Feb 11, 2025
Kind
B2
Abstract

Provided is a system for delivering and recording a dose of a medicament to a patient. Also provided is a method of administering a medicament to a patient. Additionally provided is a method of tracking usage of a medicament by a patient through a pen.

Claims (39)

1. A system, comprising:

an injection pen device configured to administer medicine to a patient; and

a software application installable on a mobile communication device in communication with the injection pen device, the mobile communication device having one or more processors and one or more processor-readable media storing the software application which, when executed by the one or more processors, causes performance of:

determining a blood glucose level of the patient;

determining a rate of change of the blood glucose level;

determining a blood glucose trend based on the rate of change of the blood glucose level;

calculating a recommended dose of medicine for administering to the patient via the injection pen device based on the blood glucose level and the blood glucose trend; and

displaying the recommended dose of medicine via at least one of a display of the injection pen device or a display of the mobile communication device.

2. The system according to claim 1 , wherein the software application, when executed by the one or more processors, further causes performance of determining the blood glucose level of the patient prior to administering of medicine to the patient via the injection pen device.

3. The system according to claim 1 , wherein the software application, when executed by the one or more processors, further causes performance of determining the rate of change of the blood glucose level of the patient prior to administering of medicine to the patient via the injection pen device.

4. The system according to claim 1 , wherein the software application, when executed by the one or more processors, further causes performance of identifying a pattern of the patient's use of the injection pen device to administer the medicine.

5. The system according to claim 4 , wherein the software application, when executed by the one or more processors, further causes performance of determining a deviation from the pattern and generating a notification based on the deviation.

6. The system according to claim 1 , wherein the mobile communication device is a smart phone.

7. The system according to claim 1 , wherein the injection pen device includes a lockout that prevents administering of a dose of the medicine that exceeds the recommended dose of medicine.

8. The system according to claim 7 , wherein the software application, when executed by the one or more processors, further causes performance of overriding the lockout to enable administering of the dose of the medicine that exceeds the recommended dose of medicine.

9. The system according to claim 1 , wherein the software application, when executed by the one or more processors, further causes performance of determining an amount of medicine on board of the patient, wherein calculating the recommended dose of the medicine is further based on the amount of medicine on board of the patient.

10. A system, comprising:

one or more processors; and

one or more processor-readable media storing instructions which, when executed by the one or more processors, cause performance of:

determining a blood glucose level of a patient;

determining a rate of change of the blood glucose level;

determining a blood glucose trend based on the rate of change of the blood glucose level;

calculating a recommended dose of medicine for administering to the patient via an injection pen device based on the blood glucose level and the blood glucose trend; and

displaying the recommended dose of medicine via at least one of a display of the injection pen device or a display of a mobile communication device in communication with the injection pen device.

11. The system according to claim 10 , wherein the one or more processor-readable media further store instructions which, when executed by the one or more processors, cause performance of determining the blood glucose level of the patient prior to administering of medicine to the patient via the injection pen device.

12. The system according to claim 10 , wherein the one or more processor-readable media further store instructions which, when executed by the one or more processors, cause performance of determining the rate of change of the blood glucose level of the patient prior to administering of medicine to the patient via the injection pen device.

13. The system according to claim 10 , wherein the one or more processor-readable media further store instructions which, when executed by the one or more processors, cause performance of identifying a pattern of the patient's use of the injection pen device to administer the medicine.

14. The system according to claim 13 , wherein the one or more processor-readable media further store instructions which, when executed by the one or more processors, cause performance of determining a deviation from the pattern and generating a notification based on the deviation.

15. The system according to claim 10 , wherein the one or more processor-readable media further store instructions which, when executed by the one or more processors, cause performance of determining an amount of medicine on board of the patient, wherein calculating the recommended dose of the medicine is further based on the amount of medicine on board of the patient.

16. One or more non-transitory processor readable media storing instructions which, when executed by one or more processors, cause performance of a method comprising:

determining a blood glucose level of a patient;

determining a rate of change of the blood glucose level;

determining a blood glucose trend based on the rate of change of the blood glucose level;

calculating a recommended dose of medicine for administering to the patient via an injection pen device based on the blood glucose level and the blood glucose trend; and

displaying the recommended dose of medicine via at least one of a display of the injection pen device or a display of a mobile communication device in communication with the injection pen device.

17. The one or more non-transitory processor-readable media according to claim 16 , wherein the one or more non-transitory processor-readable media store further instructions which, when executed by the one or more processors, cause performance of determining an amount of medicine on board of the patient, wherein calculating the recommended dose of the medicine is further based on the amount of medicine on board of the patient.

18. The one or more non-transitory processor-readable media according to claim 16 , wherein the one or more non-transitory processor-readable media store further instructions which, when executed by the one or more processors, cause performance of identifying a pattern of the patient's use of the injection pen device to administer the medicine.

19. The one or more non-transitory processor-readable media according to claim 18 , wherein the one or more non-transitory processor-readable media store further instructions which, when executed by the one or more processors, cause performance of determining a deviation from the pattern and generating a notification based on the deviation.

20. The one or more non-transitory processor-readable media according to claim 16 , wherein the one or more non-transitory processor-readable media store further instructions which, when executed by the one or more processors, cause performance of determining the blood glucose level of the patient prior to administering of medicine to the patient via the injection pen device.

Assignments (3)
SECURITY INTEREST Recorded Jan 16, 2026
From: MEDTRONIC MINIMED, INC.; COMPANION MEDICAL, INC.
To: CITIBANK, N.A.
Reel/Frame 074394/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2023
From: MENSINGER, MICHAEL ROBERT; SAINT, SEAN
To: COMPANION MEDICAL, INC.
Reel/Frame 063272/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2023
From: COMPANION MEDICAL, INC.
To: MEDTRONIC MINIMED, INC.
Reel/Frame 063272/0558 →
Continuity (4)
Continuation 16784061 · Feb 6, 2020
Continuation 15025026
Provisional Application 61883163 · Sep 26, 2013
Related Publication 20230241318A1 · Aug 3, 2023
References Cited (97)
US 7591801B2 · Brauker et al. · 2009 [cited by applicant]
US 7905833B2 · Brister et al. · 2011 [cited by applicant]
US 7976492B2 · Brauker et al. · 2011 [cited by applicant]
US 8229535B2 · Mensinger et al. · 2012 [cited by applicant]
US 8231531B2 · Brister et al. · 2012 [cited by applicant]
US 8460231B2 · Brauker et al. · 2013 [cited by applicant]
US 8565848B2 · Brister et al. · 2013 [cited by applicant]
US 8591455B2 · Mensinger et al. · 2013 [cited by applicant]
US 8663109B2 · Brister et al. · 2014 [cited by applicant]
US 8721585B2 · Mensinger et al. · 2014 [cited by applicant]
US 8750955B2 · Mensinger et al. · 2014 [cited by applicant]
US 8808228B2 · Brister et al. · 2014 [cited by applicant]
US 8882741B2 · Brauker et al. · 2014 [cited by applicant]
US 8920401B2 · Brauker et al. · 2014 [cited by applicant]
US 8926585B2 · Brauker et al. · 2015 [cited by applicant]
US 9020572B2 · Mensinger et al. · 2015 [cited by applicant]
US 9050413B2 · Brauker et al. · 2015 [cited by applicant]
US 9143569B2 · Mensinger et al. · 2015 [cited by applicant]
US 9155843B2 · Brauker et al. · 2015 [cited by applicant]
US 9446194B2 · Kamath et al. · 2016 [cited by applicant]
US 9775543B2 · Brister et al. · 2017 [cited by applicant]
US 9937293B2 · Brauker et al. · 2018 [cited by applicant]
US 9996668B2 · Reihman et al. · 2018 [cited by applicant]
US 10169539B2 · Reihman et al. · 2019 [cited by applicant]
US 10278580B2 · Brister et al. · 2019 [cited by applicant]
US 11628255B2 · Mensinger et al. · 2023 [cited by applicant]
US 20020096543A1 · Juselius · 2002 [cited by examiner]
US 20050182358A1 · Veit · 2005 [cited by examiner]
US 20050192557A1 · Brauker et al. · 2005 [cited by applicant]
US 20060036144A1 · Brister et al. · 2006 [cited by applicant]
US 20070038044A1 · Dobbles et al. · 2007 [cited by applicant]
US 20070173708A9 · Dobbles et al. · 2007 [cited by applicant]
US 20080262469A1 · Brister et al. · 2008 [cited by applicant]
US 20090036771A1 · Fago et al. · 2009 [cited by applicant]
US 20090216103A1 · Brister et al. · 2009 [cited by applicant]
US 20090240120A1 · Mensinger et al. · 2009 [cited by applicant]
US 20090240128A1 · Mensinger et al. · 2009 [cited by applicant]
US 20090240193A1 · Mensinger et al. · 2009 [cited by applicant]
US 20090299276A1 · Brauker et al. · 2009 [cited by applicant]
US 20100168661A1 · Veit · 2010 [cited by examiner]
US 20100185075A1 · Brister et al. · 2010 [cited by applicant]
US 20100261987A1 · Kamath et al. · 2010 [cited by applicant]
US 20100331656A1 · Mensinger et al. · 2010 [cited by applicant]
US 20100331657A1 · Mensinger et al. · 2010 [cited by applicant]
US 20110009727A1 · Mensinger et al. · 2011 [cited by applicant]
US 20110184343A1 · Veit · 2011 [cited by examiner]
US 20110270158A1 · Brauker et al. · 2011 [cited by applicant]
US 20110313349A1 · Krulevitch · 2011 [cited by examiner]
US 20120186581A1 · Brauker et al. · 2012 [cited by applicant]
US 20120190953A1 · Brauker et al. · 2012 [cited by applicant]
US 20120191063A1 · Brauker et al. · 2012 [cited by applicant]
US 20120215201A1 · Brauker et al. · 2012 [cited by applicant]
US 20120220979A1 · Brauker et al. · 2012 [cited by applicant]
US 20120232520A1 · Sloan · 2012 [cited by examiner]
US 20120238852A1 · Brauker et al. · 2012 [cited by applicant]
US 20120296311A1 · Brauker et al. · 2012 [cited by applicant]
US 20130035575A1 · Mayou et al. · 2013 [cited by applicant]
US 20130035865A1 · Mayou et al. · 2013 [cited by applicant]
US 20130035871A1 · Mayou et al. · 2013 [cited by applicant]
US 20130197479A1 · Butler · 2013 [cited by examiner]
US 20140012117A1 · Mensinger et al. · 2014 [cited by applicant]
US 20140012118A1 · Mensinger et al. · 2014 [cited by applicant]
US 20140012510A1 · Mensinger et al. · 2014 [cited by applicant]
US 20140012511A1 · Mensinger et al. · 2014 [cited by applicant]
US 20140114158A1 · Brister et al. · 2014 [cited by applicant]
US 20140114161A1 · Kamath et al. · 2014 [cited by applicant]
US 20140257065A1 · Walsh · 2014 [cited by applicant]
US 20140288494A1 · Brister et al. · 2014 [cited by applicant]
US 20150351683A1 · Brauker et al. · 2015 [cited by applicant]
US 20160066843A1 · Mensinger et al. · 2016 [cited by applicant]
US 20160081632A1 · Kamath et al. · 2016 [cited by applicant]
US 20160101232A1 · Kamath et al. · 2016 [cited by applicant]
US 20170068799A1 · Mensinger · 2017 [cited by examiner]
US 20170124272A1 · Reihman et al. · 2017 [cited by applicant]
US 20170124275A1 · Reihman et al. · 2017 [cited by applicant]
US 20170124350A1 · Reihman et al. · 2017 [cited by applicant]
US 20170131993A1 · Salameh et al. · 2017 [cited by applicant]
US 20170132120A1 · Salameh et al. · 2017 [cited by applicant]
US 20170185283A1 · Bhavaraju et al. · 2017 [cited by applicant]
US 20170185284A1 · Bhavaraju · 2017 [cited by applicant]
US 20170270276A1 · Saint et al. · 2017 [cited by applicant]
US 20170286194A1 · Morris et al. · 2017 [cited by applicant]
US 20170286614A1 · Morris et al. · 2017 [cited by applicant]
US 20170366617A1 · Mensinger et al. · 2017 [cited by applicant]
US 20170367627A1 · Brister et al. · 2017 [cited by applicant]
US 20180185587A1 · Brauker et al. · 2018 [cited by applicant]
US 20180303417A1 · Mensinger et al. · 2018 [cited by applicant]
US 20180353698A1 · Saint et al. · 2018 [cited by applicant]
US 20190015020A1 · Brister et al. · 2019 [cited by applicant]
US 20190035500A1 · Saint et al. · 2019 [cited by applicant]
US 20190125224A1 · Kamath et al. · 2019 [cited by applicant]
US 20190132801A1 · Kamath et al. · 2019 [cited by applicant]
US 20190173885A1 · Kamath et al. · 2019 [cited by applicant]
WO 2013053695A1 · 2013 [cited by applicant]
Takahashi et al. 2008, “A survey of insulin-dependent diabetes-part I: therapies and devices,” Int J Telemed Appl. 2008;2008: 639019. doi: 10.1155/2008/639019. [cited by examiner]
Spanakis et al 2012, “Diabetes management using modern information and communication technologies and new care models,” Interact J Med Res. Oct. 4, 2012;1(2):e8. doi: 10.2196/ijmr.2193. [cited by examiner]
Canadian Office Action issued in corresponding Canadian Application No. 2,925,458 dated Nov. 9, 2020, 4 pages. [cited by applicant]